EUVIMEDEUVIMED entdecken
Vergleichsstudie

Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models

Gloria Nnadwa Alhassan

Therapeutic Innovation & Regulatory Science · 2026-07 · 60 (4) · 1084-1093

DOI: 10.1007/s43441-026-00960-w ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 28.03.2026. Verfasst von Gloria Nnadwa Alhassan. Beteiligte Einrichtung: Department of Nursing, Faculty of Health Sciences, Istanbul Gelişim University, Istanbul, Turkey. gnalhassan@gelisim.edu.tr. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Acrylamides, Lung Neoplasms. Die Arbeit nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Health technology assessments (HTAs) for targeted therapies like osimertinib require models capturing individual pharmacokinetic/pharmacodynamic (PK/PD) variability in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Traditional models often fail to reflect these dynamics adequately. This study compared a pharmacometric-based model (PMX) with four traditional frameworks to evaluate osimertinib's cost-utility from a healthcare payer perspective. A virtual cohort of 1,000 patients with advanced EGFR-mutant NSCLC received osimertinib (80 mg daily) or comparator first-line EGFR-tyrosine kinase inhibitors (gefitinib/erlotinib). Models projected survival, adverse events (AEs), quality-adjusted life years (QALYs), and costs over 2 years. ICURs used PMX as benchmark. The PMX model yielded highest QALYs (1.48) and lowest ICUR ($82,000/QALY vs. comparator), outperforming traditional models (ICUR deviations - 21% to + 40%). TTE exponential showed most divergence due to constant hazard. Probabilistic analyses confirmed PMX superiority across willingness-to-pay thresholds. Pharmacometric models, enabling individualized dosing and exposure-driven effects, provide more biologically plausible estimates, supporting their integration into HTAs for precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAniline CompoundsAcrylamidesLung NeoplasmsAntineoplastic AgentsProtein Kinase InhibitorsHumansIndolesPyrimidinesErbB ReceptorsCost-Benefit AnalysisQuality-Adjusted Life YearsMutationEconomics, PharmaceuticalModels, EconomicCost-Effectiveness AnalysisGefitinib

Stichwörter der Autor:innen

Cost-Utility analysisEGFR-Mutant NSCLCHealth technology assessmentOsimertinibPharmacoeconomic modelingPharmacometric model

Substanzen

osimertinibAniline CompoundsIndolesAcrylamidesPyrimidinesErbB ReceptorsAntineoplastic AgentsEGFR protein, humanProtein Kinase InhibitorsGefitinib

Autor:innen und Institutionen

  • Department of Nursing, Faculty of Health Sciences, Istanbul Gelişim University, Istanbul, Turkey. gnalhassan@gelisim.edu.tr.

Zitieren

APA

Alhassan, G. N. (2026). Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models. Therapeutic Innovation & Regulatory Science, 60(4), 1084-1093. https://doi.org/10.1007/s43441-026-00960-w

Vancouver

Alhassan GN. Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models. Therapeutic Innovation & Regulatory Science. 2026;60(4):1084-1093. doi:10.1007/s43441-026-00960-w

BibTeX
@article{Alhassan2026,
  author = {Alhassan, Gloria Nnadwa},
  title = {Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  volume = {60},
  number = {4},
  pages = {1084--1093},
  doi = {10.1007/s43441-026-00960-w}
}
Kostenlos starten →